HK1201446A1 - Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof - Google Patents

Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof Download PDF

Info

Publication number
HK1201446A1
HK1201446A1 HK15101938.6A HK15101938A HK1201446A1 HK 1201446 A1 HK1201446 A1 HK 1201446A1 HK 15101938 A HK15101938 A HK 15101938A HK 1201446 A1 HK1201446 A1 HK 1201446A1
Authority
HK
Hong Kong
Prior art keywords
bone
disorders
overactivation
fgfr3
polypeptides
Prior art date
Application number
HK15101938.6A
Other languages
English (en)
Chinese (zh)
Inventor
Philippe Crine
Florent Elefteriou
Original Assignee
Alexion Pharmaceuticals, Inc.
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc., Vanderbilt University filed Critical Alexion Pharmaceuticals, Inc.
Publication of HK1201446A1 publication Critical patent/HK1201446A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15101938.6A 2011-10-19 2012-10-18 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof HK1201446A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549047P 2011-10-19 2011-10-19
US61/549,047 2011-10-19
US201261649717P 2012-05-21 2012-05-21
US61/649,717 2012-05-21
PCT/US2012/060869 WO2013059491A1 (en) 2011-10-19 2012-10-18 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1201446A1 true HK1201446A1 (en) 2015-09-04

Family

ID=48141235

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101938.6A HK1201446A1 (en) 2011-10-19 2012-10-18 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof

Country Status (8)

Country Link
EP (2) EP3488861B1 (OSRAM)
JP (1) JP6118807B2 (OSRAM)
KR (1) KR20140084201A (OSRAM)
CA (1) CA2852874A1 (OSRAM)
ES (2) ES2714406T3 (OSRAM)
HK (1) HK1201446A1 (OSRAM)
SG (1) SG11201401605QA (OSRAM)
WO (2) WO2013058833A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
BR112017011900A2 (pt) 2014-12-05 2018-02-27 Alexion Pharma Inc tratamento de ataques com fosfatase alcalina recombinante
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6693134B2 (ja) * 2015-02-02 2020-05-13 東ソー株式会社 リンカー配列を有する抗体及びそれを用いた測定法
CA2981103A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
KR102789821B1 (ko) * 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
DK4089113T3 (da) 2015-03-31 2024-02-05 Sorriso Pharmaceuticals Inc Polypeptider
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
AU2016308624B2 (en) * 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) * 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US11186832B2 (en) * 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US20190218274A1 (en) * 2016-05-06 2019-07-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) * 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2022007114A (es) * 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
CN116848146A (zh) * 2020-09-03 2023-10-03 I·S·Y·陈 可溶性碱性磷酸酶构建体和包含编码可溶性碱性磷酸酶构建体的多核苷酸的表达载体
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos
AU2023232162A1 (en) * 2022-03-11 2024-10-24 Avirmax Biopharma Inc. Compositions and methods for expressing therapeutics
WO2024094747A1 (en) 2022-11-02 2024-05-10 Novo Nordisk A/S Cnp compounds
CN116286763B (zh) * 2023-02-28 2024-06-25 西北工业大学 一种热稳定性提高的胱硫醚β-合成酶突变体及应用
TW202513806A (zh) * 2023-06-07 2025-04-01 美商拜奧馬林製藥公司 高通量篩選與身材矮小相關之基因變異體

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69108830T2 (de) 1990-04-20 1995-09-14 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
SG2013034475A (en) 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
CN101068575A (zh) 2004-12-01 2007-11-07 建新公司 向肝脏定向递送遗传物质的方法
TW200833840A (en) * 2006-10-25 2008-08-16 Amgen Inc Toxin peptide therapeutic agents
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
AU2008250945B2 (en) 2007-05-11 2013-12-12 Alexion Pharmaceuticals, Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
US20100310561A1 (en) 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
CA2693303C (en) 2007-07-20 2017-11-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US20100184680A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體

Also Published As

Publication number Publication date
ES2714406T3 (es) 2019-05-28
ES2944087T3 (es) 2023-06-19
WO2013058833A8 (en) 2013-06-13
EP2768526A1 (en) 2014-08-27
CA2852874A1 (en) 2013-04-25
WO2013059491A1 (en) 2013-04-25
KR20140084201A (ko) 2014-07-04
JP6118807B2 (ja) 2017-04-19
WO2013058833A1 (en) 2013-04-25
EP2768526A4 (en) 2015-04-15
EP2768526B1 (en) 2018-12-05
EP3488861B1 (en) 2023-02-15
SG11201401605QA (en) 2014-09-26
EP3488861A1 (en) 2019-05-29
JP2015502336A (ja) 2015-01-22

Similar Documents

Publication Publication Date Title
HK1201446A1 (en) Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2012088608A8 (en) Compositions comprising natriuretic peptides and methods of use thereof
HK1250238A1 (zh) 抗angptl8抗体及其用途
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
EA201990619A1 (ru) Fgf21 мутанты и их применение
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MY161844A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2014004549A3 (en) Anti-mesothelin binding proteins
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
UY38740A (es) Mutantes de fgf21 y usos del mismo
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
PH12017500864A1 (en) Anti-notch1 antibodies
EA201401065A1 (ru) Ang2-связывающие молекулы
CA2894869C (en) Solution formulations of engineered anti-il-23p19 antibodies
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2012154695A3 (en) Treatment of polycystic disease
NZ702178A (en) Lingo-2 antagonists for treatment of conditions involving motor neurons
BR112014031841A2 (pt) formulação farmacêutica
MX2015016054A (es) Terapia de combinacion anti-quimiocina del ligando 2 del motif c-c y anti-lisil oxidasa-tipo 2 para el tratamiento de escleroderma.
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2011017564A3 (en) Identification and use of compounds for treating persistent pain
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
HK1218373A1 (zh) 用於治療年齡相關失調的重組膠原蛋白7的給予
UA55888U (ru) Способ лечения дегенеративно-дистрофических заболеваний позвоночника